Latest / The Onco Life Podcast
Breakthrough in Lung Cancer Treatment: Lurbinectedin and Atezolizumab Combo Extends Survival in ES-SCLC Patients
A new FDA-approved combination of lurbinectedin and atezolizumab is changing the outlook for patients with extensive-stage small cell lung cancer (ES-SCLC). This first-line maintenance therapy offers a major step forward in extending survival and disease control after initial treatment.In this episode, you’ll learn: • How the lurbinectedin + atezolizumab combo improves survival and progression-free outcomes • Key findings from the IMforte Phase 3 clinical trial • What makes this treatment a new first-line maintenance option for ES-SCLC • Important safety and monitoring considerations for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.